The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...
In wrapping up the 2023-24 term and embarking on the 2024-25 term, the Supreme Court was asked to decide a number of intellectual property cases. The ...
GM has filed a patent application for a torsion-assisted folding vehicle seat back system, potentially making it easier to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback